{"organizations": [], "uuid": "fee86bc0d393e68029830f362a222c38ea1be4d2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/30/pr-newswire-array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018.html", "country": "US", "domain_rank": 767, "title": "Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.112, "site_type": "news", "published": "2018-01-30T17:00:00.000+02:00", "replies_count": 0, "uuid": "fee86bc0d393e68029830f362a222c38ea1be4d2"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/30/pr-newswire-array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018.html", "ord_in_thread": 0, "title": "Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018", "locations": [], "entities": {"persons": [{"name": "ron squarer", "sentiment": "none"}], "locations": [{"name": "boulder", "sentiment": "none"}, {"name": "colo.", "sentiment": "none"}], "organizations": [{"name": "array biopharma inc.", "sentiment": "negative"}, {"name": "genentech", "sentiment": "none"}, {"name": "roche", "sentiment": "none"}, {"name": "loxo oncology", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}, {"name": "biopharma array biopharma inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOULDER, Colo., Jan. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, February 6, 2018. Ron Squarer, Chief Executive Officer, will lead the call.\nDate:\nTuesday, February 6, 2018\nTime:\n9:00 a.m. Eastern Time\nToll-Free:\n(844) 464-3927\nToll:\n(765) 507-2598\nPass Code:\n6187887\nWebcast, including Replay and Conference Call Slides:\nhttps://edge.media-server.com/m6/p/gwxnqcbs\nAbout Array BioPharma\nArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).\nCONTACT:\nArray BioPharma\nAndrea N. Flynn, Ph.D.\nSenior Director, Investor Relations & Corporate Communications\n(303) 381-6600\nir@arraybiopharma.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018-300589831.html\nSOURCE Array BioPharma Inc.", "external_links": ["http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018-300589831.html", "https://edge.media-server.com/m6/p/gwxnqcbs"], "published": "2018-01-30T17:00:00.000+02:00", "crawled": "2018-01-30T18:30:29.004+02:00", "highlightTitle": ""}